NHS National Framework Agreement for the supply of Adalimumab Injection 1 April 2023

Concepts

• runcorn
• pharmaceutical products
• period of framework
• supply of adalimumab injection
• april
• offer reference number
• nhs national framework agreement
• authority's discretion
• project title
• south of england

Location

Description

Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection 1 April 2023 Offer reference number: CM/PHR/22/5660 CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Award Detail

CPV Codes

• 33600000 - Pharmaceutical products

Indicators

• Contract is suitable for SMEs.

Other Information

5660_02 Transparency Award Schedule 5660_02 Transparency Award Schedule.pdf 5660_03 Transparency Award Schedule 5660_03 Transparency Award Schedule.pdf 5660_04 Transparency Award Schedule 5660_04 Transparency Award Schedule.pdf 030223-2022 FTS Opportunity National Framework Agreement for Adalimumab Injection 1 April 2023 030223-2022 FTS Opportunity National Framework Agreement for Adalimumab Injection 1 April 2023.pdf 5660_01 Transparency Award Schedule 5660_01 Transparency Award Schedule.pdf Parties Appointed to the framework CM-PHR-22-5660 Parties Appointed to the framework CM-PHR-22-5660.xlsx 03 Framework Agreement and Terms and Conditions - CM_PHR_22_5660 - National Framework Agreement for Adalimumab Injection April 2023 03 Framework Agreement and Terms and Conditions - CM_PHR_22_5660 - National Framework Agreement for Adalimumab Injection April 2023.docx